CN110818660B - 用于治疗癌症的β-羟化酶抑制剂 - Google Patents

用于治疗癌症的β-羟化酶抑制剂 Download PDF

Info

Publication number
CN110818660B
CN110818660B CN201910949656.0A CN201910949656A CN110818660B CN 110818660 B CN110818660 B CN 110818660B CN 201910949656 A CN201910949656 A CN 201910949656A CN 110818660 B CN110818660 B CN 110818660B
Authority
CN
China
Prior art keywords
methyl
hydroxy
acetoxy
furyl
furanon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201910949656.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN110818660A (zh
Inventor
J·R·万兹
S·德拉蒙特
A·相原
M·J·奥尔森
J-M·托马斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhode Island Hospital
Midwestern University Glendale
Original Assignee
Rhode Island Hospital
Midwestern University Glendale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhode Island Hospital, Midwestern University Glendale filed Critical Rhode Island Hospital
Priority to CN201910949656.0A priority Critical patent/CN110818660B/zh
Publication of CN110818660A publication Critical patent/CN110818660A/zh
Application granted granted Critical
Publication of CN110818660B publication Critical patent/CN110818660B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/66—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201910949656.0A 2012-09-21 2013-09-20 用于治疗癌症的β-羟化酶抑制剂 Expired - Fee Related CN110818660B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910949656.0A CN110818660B (zh) 2012-09-21 2013-09-20 用于治疗癌症的β-羟化酶抑制剂

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261704014P 2012-09-21 2012-09-21
US61/704,014 2012-09-21
PCT/US2013/061050 WO2014047519A2 (en) 2012-09-21 2013-09-20 Inhibitors of beta-hydrolase for treatment of cancer
CN201910949656.0A CN110818660B (zh) 2012-09-21 2013-09-20 用于治疗癌症的β-羟化酶抑制剂
CN201380061004.4A CN104902889A (zh) 2012-09-21 2013-09-20 用于治疗癌症的β-水解酶抑制剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380061004.4A Division CN104902889A (zh) 2012-09-21 2013-09-20 用于治疗癌症的β-水解酶抑制剂

Publications (2)

Publication Number Publication Date
CN110818660A CN110818660A (zh) 2020-02-21
CN110818660B true CN110818660B (zh) 2023-09-12

Family

ID=50342080

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910949656.0A Expired - Fee Related CN110818660B (zh) 2012-09-21 2013-09-20 用于治疗癌症的β-羟化酶抑制剂
CN201380061004.4A Pending CN104902889A (zh) 2012-09-21 2013-09-20 用于治疗癌症的β-水解酶抑制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380061004.4A Pending CN104902889A (zh) 2012-09-21 2013-09-20 用于治疗癌症的β-水解酶抑制剂

Country Status (10)

Country Link
US (8) US9771356B2 (enExample)
EP (2) EP3345596B1 (enExample)
JP (1) JP6469009B2 (enExample)
KR (1) KR102137180B1 (enExample)
CN (2) CN110818660B (enExample)
AU (1) AU2013317791B2 (enExample)
CA (1) CA2885762C (enExample)
ES (2) ES2865412T3 (enExample)
HK (1) HK1208805A1 (enExample)
WO (2) WO2014047447A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110818660B (zh) 2012-09-21 2023-09-12 罗得岛医院 用于治疗癌症的β-羟化酶抑制剂
WO2019012159A1 (en) * 2017-07-14 2019-01-17 Protea Biopharma N.V. METHODS AND MEANS FOR DIAGNOSING AND / OR TREATING A FATIGUE-ASSOCIATED DISEASE
US10961320B2 (en) 2018-06-18 2021-03-30 Midwestern University Monoclonal antibodies targeting epitopes of ASPH
CN109364251A (zh) * 2018-12-06 2019-02-22 苏州大学 Tet蛋白在治疗抑郁症中的应用
EP3923922A4 (en) 2019-02-15 2022-03-30 Midwestern University Isotopically-stabilized tetronimide compounds

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5389673A (en) * 1992-12-08 1995-02-14 American Home Products Corporation 4- or 5-(substituted sulfonyl)methyl-3(2H)-furanones
JPH09110853A (ja) * 1995-10-12 1997-04-28 Kikkoman Corp ４‐アシルオキシフラノン誘導体又はその塩及びその製造方法
WO2003018575A1 (en) * 2001-08-24 2003-03-06 Wyeth Holdings Corporation 5-substituted-3(2h)-furanones useful for inhibition of farnesyl-protein transferase
WO2003064403A1 (en) * 2002-01-31 2003-08-07 Galileo Laboratories, Inc. Furanone derivatives
WO2004035812A2 (en) * 2002-10-16 2004-04-29 Isis Innovation Limited Asparaginyl hydroxylases and modulators thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE39717C (de) H. LEHMANN in München, Enhuberstr. 5 part Bleistifthalter
DD39717A (enExample) *
WO1987000729A1 (en) * 1985-08-02 1987-02-12 Chevron Research Company Herbicidal 2-(oxa or thia heterocycle)5-amino-3-oxo-4-(substituted-phenyl)-2,3-dihydrofurans
US5698585A (en) * 1995-04-13 1997-12-16 Kikkoman Corporation Pharmaceutical preparation for prevention and/or treatment for cataract
UA57002C2 (uk) 1995-10-13 2003-06-16 Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування
US5877193A (en) * 1996-07-19 1999-03-02 Hoffmann-La Roche Inc. Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
TW528755B (en) * 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
ATE244232T1 (de) * 1997-03-14 2003-07-15 Merck Frosst Canada Inc (methylsulfonyl)phenyl-2-(5h)-furanone mit sauerstoff-bindung als cox-2-hemmer
US20030031670A1 (en) 1999-11-08 2003-02-13 Jack R. Wands Diagnosis and treatment of malignant neoplasms
US6835370B2 (en) 1999-11-08 2004-12-28 Rhode Island Hospital Diagnosis and treatment of malignant neoplasms
US20050123545A1 (en) 1999-11-08 2005-06-09 Wands Jack R. Diagnosis and treatment of malignant neoplasms
AU2002950862A0 (en) * 2002-08-19 2002-09-12 Biosignal Pty Ltd Furanone derivatives and methods of making same
WO2005070916A1 (en) * 2004-01-09 2005-08-04 Eli Lilly And Company Thiophene and furan compounds
EP2227233B1 (en) 2007-11-30 2013-02-13 Newlink Genetics Ido inhibitors
EP2576532B1 (en) * 2010-06-07 2018-07-18 Novomedix, LLC Furanyl compounds and the use thereof
CN110818660B (zh) 2012-09-21 2023-09-12 罗得岛医院 用于治疗癌症的β-羟化酶抑制剂

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5389673A (en) * 1992-12-08 1995-02-14 American Home Products Corporation 4- or 5-(substituted sulfonyl)methyl-3(2H)-furanones
JPH09110853A (ja) * 1995-10-12 1997-04-28 Kikkoman Corp ４‐アシルオキシフラノン誘導体又はその塩及びその製造方法
WO2003018575A1 (en) * 2001-08-24 2003-03-06 Wyeth Holdings Corporation 5-substituted-3(2h)-furanones useful for inhibition of farnesyl-protein transferase
WO2003064403A1 (en) * 2002-01-31 2003-08-07 Galileo Laboratories, Inc. Furanone derivatives
WO2004035812A2 (en) * 2002-10-16 2004-04-29 Isis Innovation Limited Asparaginyl hydroxylases and modulators thereof

Also Published As

Publication number Publication date
ES2865412T3 (es) 2021-10-15
CA2885762C (en) 2022-05-03
ES2660822T3 (es) 2018-03-26
CA2885762A1 (en) 2014-03-27
US10710995B2 (en) 2020-07-14
US10787445B2 (en) 2020-09-29
US20150210677A1 (en) 2015-07-30
JP6469009B2 (ja) 2019-02-13
US20190002453A1 (en) 2019-01-03
WO2014047519A2 (en) 2014-03-27
US10351555B2 (en) 2019-07-16
US20220251076A1 (en) 2022-08-11
US20210032233A1 (en) 2021-02-04
KR20150079616A (ko) 2015-07-08
US9771356B2 (en) 2017-09-26
WO2014047447A2 (en) 2014-03-27
CN110818660A (zh) 2020-02-21
AU2013317791B2 (en) 2018-05-10
EP3345596B1 (en) 2021-01-20
HK1208805A1 (zh) 2016-03-18
EP2897607A2 (en) 2015-07-29
US20190300519A1 (en) 2019-10-03
US20180009798A1 (en) 2018-01-11
US10106532B2 (en) 2018-10-23
US20180237427A1 (en) 2018-08-23
EP3345596A3 (en) 2018-10-03
WO2014047519A3 (en) 2014-05-30
EP3345596A2 (en) 2018-07-11
WO2014047447A3 (en) 2015-07-30
AU2013317791A1 (en) 2015-05-07
KR102137180B1 (ko) 2020-07-24
EP2897607A4 (en) 2016-10-05
JP2015531351A (ja) 2015-11-02
US20200361925A1 (en) 2020-11-19
EP2897607B1 (en) 2017-11-22
CN104902889A (zh) 2015-09-09

Similar Documents

Publication Publication Date Title
US20220251076A1 (en) Inhibitors of Beta-Hydoxylase for Treatment of Cancer
TWI567059B (zh) 吡咯啶－２，５－二酮衍生物、醫藥組合物及用做為ｉｄｏ１抑制劑之方法
CA2464367C (en) Bicyclic compounds
BR112016005606B1 (pt) Composto, composição farmacêutica, e usos de um composto
WO2024188107A1 (zh) 含噻唑结构的吲哚啉类化合物及其制备方法和应用
US11897857B2 (en) Isotopically-stabilized tetronimide compounds
US20250162994A1 (en) Dual lsd1/hdac inhibitors
JPH0873451A (ja) 新規な２，３−ジヒドロベンゾフラン誘導体、その製造方法および用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20230912